ecancer

How should we handle talimogene laherparepvec (T-VEC)?

Prof Axel Hauschild - University of Kiel, Kiel, Germany

5 Nov 2015

New challenges in drug combination and strategies

Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK

5 Nov 2015

Targeting N-RAS mutated tumours

Prof Axel Hauschild - University of Kiel, Kiel, Germany

30 Oct 2015

HVEM expression in melanoma metastasis: prognosis correlation

Prof Daniel Olive - Marseilles Cancer Research Center, Marseilles, France

30 Oct 2015

Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma

Prof Axel Hauschild - University of Kiel, Kiel, Germany

30 Oct 2015

Systemic immunotherapy and radiotherapy combination shows promise in advanced skin cancer

Dr Susan Hiniker - Stanford University, Stanford, USA

27 Oct 2015

HPV vaccines for cancer prevention

Prof Jack Cuzick - Queen Mary University of London, London, UK

1 Oct 2015

ECC 2015 scientific highlights

Prof Peter Naredi - University of Gothenburg, Gothenburg, Sweden

30 Sep 2015

Time between melanoma excision and sentinel node biopsy does not affect survival

Charlotte Oude Ophuis - Erasmus MC Cancer Institute, Rotterdam, Netherlands

30 Sep 2015

COMBI-V: Melanoma survival improved by targeted drug combination

Prof Caroline Robert - Institute Gustave Roussy, Villejuif, France

28 Sep 2015

Melanoma immunotherapy latest and TVEC plus pembrolizumab

Dr Georgina Long - University of Sydney, Sydney, Australia

27 Sep 2015

The p-medicine project and ECRIN

Jacques Demotes - ECRIN

2 Sep 2015

More from ecancer